{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"106"}],"title":"No handicap"},{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"21"}],"title":"Mild-moderate handicap"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}],"title":"Severe handicap"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"description":"The HHIA-S measures a person's perceived hearing handicap. Total score ranges from 0 to 40, with a higher score indicating more severe perceived hearing handicap, categorized as follows:\n\n* No handicap: 0-8.\n* Mild-moderate handicap: 10-24.\n* Severe handicap: 26-40.","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had outcome measure data.","reportingStatus":"POSTED","timeFrame":"6 months after end of treatment. Treatment lasts 6-7 weeks.","title":"Number of Participants by HHIA-S Category at 6 Months After End of Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}